

# Emerging intravesical therapies for the management of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer: Charting a path forward

Ali Cyrus Chehroudi, MD; Peter C. Black, MD

Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

Cite as: *Can Urol Assoc J* 2020;14(6):204-13. <http://dx.doi.org/10.5489/cuaj.6101>


Published online January 20, 2020

## Abstract

Management of patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, non-muscle-invasive bladder cancer (NMIBC) presents a formidable clinical challenge that requires urologists to weigh the competing risks of progression during further intravesical therapy vs. the morbidity of radical cystectomy. The prognosis of high-risk NMIBC recurring after BCG depends on the adequacy of prior BCG, timing of recurrence, and tumor histology. The standard of care is currently radical cystectomy, as effective salvage intravesical therapy has not been established. The development of bladder-sparing treatments has been hampered to date by inconsistent definitions of BCG failure and difficulties in identifying appropriate control treatments in clinical trials. Despite these limitations, the spectrum of salvage therapy is expanding to include enhanced intravesical chemo-, gene, and immuno-therapies. In this review, we provide an overview of these emerging agents in the context of our current understanding of BCG failure and the unique considerations for clinical trial design in this disease state.

## Introduction

Bladder cancer is the fifth most commonly diagnosed malignancy and is responsible for approximately 20 000 deaths per year in Canada and the U.S.<sup>1-3</sup> The majority ( $\approx 75\%$ ) of tumors are non-muscle-invasive. Standard therapies for non-muscle-invasive bladder cancer (NMIBC) include transurethral bladder tumor resection (TURBT) and intravesical therapy with chemotherapy or bacillus Calmette-Guérin (BCG). Despite optimal therapy, up to 80% of tumors recur, and anywhere from 0–40% progress to muscle-invasive disease, depending on risk factors.<sup>4</sup> The treatment options, especially



This article is CUA-accredited for Section 3 credits of the MOC Program of the RCPSC. Go to [www.cuaj.ca](http://www.cuaj.ca) for details.

for high-grade NMIBC that has recurred despite optimal BCG therapy, are limited. There are no established second-line salvage intravesical therapies, and the standard of care for these patients is radical cystectomy. The management of high-grade NMIBC recurring on or after BCG therapy represents a critical unmet need in urology. In this narrative review, we aim to demonstrate the gaps in current standard management of NMIBC, and to review the novel therapies on the horizon to address these gaps.

## Optimal risk-adapted therapy for NMIBC

NMIBC is stratified into low-, intermediate-, and high-risk disease states based on risk of recurrence and progression. The most important risk factors are T stage, tumor grade, presence of carcinoma in situ (CIS), tumor size, multifocality, and prior history of recurrence (Table 1).<sup>5,6</sup> Low- and intermediate-risk tumors are generally effectively managed with TURBT and judicious use of intravesical therapy.<sup>7</sup> These may recur in a high proportion of cases (40–60%). The risk of progression to higher stage disease is rare for low-risk disease, but ranges from 5–15% for intermediate-risk disease.<sup>8</sup> In contrast, high-risk patients are at increased risk of progression, measuring approximately 50% over 15 years in one series.<sup>4,9</sup> Standard of care for high-risk disease is intravesical immunotherapy with BCG. BCG is believed to augment the anti-tumor immune response by promoting T-cell recruitment, cytotoxic activity, and cytokine release.<sup>10</sup> A Cochrane review on intermediate- and high-risk NMIBC demonstrated that BCG reduced the odds of disease progression by 56% compared to TURBT alone.<sup>11</sup> BCG has also been shown to be superior to mitomycin C (MMC) in reducing recurrence (odds ratio [OR] 0.56).<sup>12</sup> The direct comparison to MMC with respect to progression is less clear,<sup>13,14</sup> but only BCG with maintenance has been shown to reduce progression in an individual trial.<sup>15</sup> Optimal BCG is delivered as a weekly induction for six weeks followed by three weekly

**Table 1. Risk-stratification for NMIBC (2016 AUA guidelines)**

Low-risk	Intermediate-risk	High-risk
Low-grade solitary Ta $\leq$ 3 cm	Recurrence within 1-year low-grade Ta	High-grade T1
Papillary neoplasm of low malignant potential	Solitary low-grade Ta $>$ 3 cm	Any recurrent, high-grade Ta
	Low-grade Ta, multifocal	High-grade Ta, $>$ 3 cm (or multifocal)
	High-grade Ta, $\leq$ 3 cm*	Any CIS
	Low-grade T1*	Any BCG failure in high-grade case
		Any variant histology
		Any LVI
		Any high-grade prostatic urethral involvement

\*EAU and CUA guidelines for non-muscle-invasive bladder cancer classify these tumors as high-risk. The downgrading of these tumors to intermediate-risk by the AUA was based on the lack of BCG maintenance in studies assessing progression and how the panel felt these tumors would behave with adequate BCG. AUA: American Urological Association; BCG bacillus Calmette-Guérin; CIS: carcinoma in situ; CUA: Canadian Urological Association; EAU: European Association of Urology; LVI: lymphovascular invasion; NMIBC: non-muscle-invasive bladder cancer.

maintenance instillations at three, six, 12, 18, 24, 30, and 36 months, as per prior randomized controlled trials (RCTs), which demonstrate superior oncological outcomes with this maintenance protocol.<sup>15,16</sup>

## Defining recurrence after BCG

Unfortunately, BCG will fail in 30–40% of patients with NMIBC.<sup>17</sup> High-grade recurrence after BCG presents a challenging scenario, and the evidence for optimal treatment of these patients is difficult to interpret because of varied definitions of BCG failure. Technically, a BCG failure can be taken to represent any recurrence during or after BCG therapy. However, several factors help to stratify BCG failure, including the timing of recurrence and the adequacy of prior BCG. BCG failure is often stratified into BCG-relapsing, -refractory, and -unresponsive disease, assuming adequate BCG induction and maintenance<sup>18</sup> (Fig. 1). BCG-relapsing disease can be heterogenous depending on the time to relapse. An early relapse has a similar outcome to BCG-refractory disease, but late relapses may respond to additional BCG<sup>19</sup> and generally have a more favorable outcome.<sup>20,21</sup> An early relapse is defined as recurrence within six months of the last BCG dose for papillary (Ta/T1) NMIBC and within 12 months for CIS.<sup>21</sup> BCG-refractory NMIBC is defined as high-grade recurrence or failure to eradicate disease with induction and the first cycle of maintenance BCG (or second induction cycle) if the recurrence is CIS or high-grade Ta disease. If the recurrence is a high-grade


T1 tumor, it is considered BCG-refractory after induction BCG alone. Any patient with BCG-refractory NMIBC or an early relapse is termed to be BCG-unresponsive. This is an important definition for both clinical practice and clinical trial design, as it delineates a group of patients who are unlikely to benefit from additional BCG.

The natural history of BCG-refractory disease is often progression to muscle-invasive cancer, metastasis, and even death.<sup>9,22</sup> It is essential to re-evaluate the upper tract and prostatic urethra in patients with suspected recurrence after BCG since approximately 50% of patients will harbor disease in these locations.<sup>23</sup> Historical data suggest that the risk of metastasis in patients with BCG failure reaches 50% after three additional cycles of BCG.<sup>24</sup> Complete response rates to a second course of BCG range from 20–50%<sup>25</sup> depending on the category of BCG failure, tumor histology, and presence of CIS, which is associated with 50% progression.<sup>26</sup> Early radical cystectomy provides the best oncological outcomes, with a disease-free rate greater than 90%.<sup>27</sup> All forms of salvage intravesical therapy for both BCG-refractory and relapsing disease must be considered oncologically inferior to cystectomy.<sup>6</sup>

Salvage intravesical therapy in North America often consists of BCG/interferon-alpha (BCG/IFN). The evidence in support of this regimen comes from a large prospective trial of over 400 BCG-naïve and failure patients (including both refractory and relapsing disease), which showed cancer-free rates at two years of 59% and 45%, respectively, when treated with BCG/IFN.<sup>28</sup> A subsequent re-analysis showed that response to BCG/IFN was strongly associated with the category of BCG failure.<sup>29</sup> To illustrate, BCG-refractory patients had only 34% recurrence-free survival compared to 53% for patients relapsing within 12–24 months. The largest limitation is that there are no data directly comparing BCG/IFN to BCG monotherapy, which is regarded as an appropriate therapy in the late BCG-relapsing disease space.

## Emerging chemotherapeutic agents

The use of intravesical chemotherapeutic agents, such as gemcitabine, valrubicin, epirubicin, and docetaxel as salvage therapy for BCG failure has been under investigation for at least 20 years (Table 2). Of these, only valrubicin is currently Food and Drug Administration (FDA)-approved for management of BCG-refractory CIS based on a phase 2, multicenter, single-arm trial that demonstrated a 21% complete response rate in patients with recurrent CIS.<sup>30</sup> This translated to an 8% disease-free rate at 30 months, which would likely be inadequate for FDA approval currently. While it is the only FDA-approved drug in this setting, and although there are currently no other established standard salvage therapies for BCG-unresponsive disease, valrubicin is not necessarily the most commonly used.



**Fig. 1.** Overview of standard of care for bladder cancer. \*All evaluations should comprise of cystoscopy, urine cytology, and random bladder biopsies for CIS. Papillary disease at 3 months requires resection. Any recurrence while on BCG with muscle-invasive disease is managed according to the MIBC pathway. BCG: bacillus Calmette-Guérin; CIS: carcinoma in situ; MIBC: muscle-invasive bladder cancer; NMIBC: non-muscle-invasive bladder cancer.

Intravesical gemcitabine represents a reasonable option based on trial data and its known efficacy when administered systemically for muscle-invasive and metastatic urothelial carcinoma. Gemcitabine was shown to be superior to MMC in a head-to-head RCT for BCG failure.<sup>31</sup> Another RCT comparing repeat BCG to intravesical gemcitabine showed that the latter significantly improved recurrence-free survival (19% vs. 3%), although it did not impact disease progression.<sup>32</sup> Barlow and colleagues treated 54 NMIBC (87% high-risk) BCG non-responders with intravesical docetaxel induction and maintenance with a 25% recurrence-free survival at three years and 85% disease-specific survival at five years.<sup>33</sup> Combination therapy has also been tested, with encouraging results.<sup>34</sup>

A key shortcoming in these trials is that they were conducted prior to our current understanding of optimal BCG, the importance of maintenance BCG, and risk-stratifying BCG failures. These considerations were also not reflected in older NMIBC guidelines.<sup>35</sup> Therefore, the inclusion criteria for these studies did not control for the dose/duration of BCG and time from completion of BCG to recurrence. BCG-intolerant patients were also commonly combined

with refractory/relapsing patients, and some studies included intermediate-risk patients. Lastly, since these are mostly single-arm efficacy trials without a control group, we cannot conclude whether the above treatments are superior to repeat BCG. Despite these limitations, there is little disagreement within the urological community that the outcomes of salvage intravesical chemotherapy in patients recurring after BCG are suboptimal. We can cautiously conclude that approximately 70–80% will have a recurrence within two years after starting salvage chemotherapy.

### Clinical trial design and BCG failure

Given the limited utility of salvage intravesical chemotherapy in the management of BCG failure, there is a large unmet need for novel bladder-sparing therapies. Indeed, since 1959 there have only been two new treatments approved by the FDA (valrubicin and thiotepa), neither of which has demonstrated robust anti-tumor response. Much of the limited development in NMIBC therapeutics stems from ethical and logistical questions that form the backbone of designing meaningful clinical trials for BCG failure:

**Table 2. Key trials for chemotherapy in BCG failures**

Agent	Study	Study design	Inclusion criteria	Outcome
Valrubicin	Steinberg et al <sup>1</sup>	Phase 2, single-arm trial	- Any failure or recurrence after 6-week induction BCG for CIS - BCG intolerant	- 20% complete response - 8% disease-free at 30 months - 50% required cystectomy
Gemcitabine	Adeo et al <sup>2</sup>	RCT of intravesical gemcitabine vs. MMC	- Any recurrence or progression after BCG of unspecified dose/duration. - BCG ineligible patients	- 72% of gemcitabine and 61% of MMC patients free of disease at median of 36 months
Gemcitabine	Dalbagni et al <sup>3</sup>	Phase 2, single-arm trial	- Disease that was deemed refractory to BCG of unspecified dose/duration - BCG intolerance	- 39% complete response - 21% disease-free at 1 year
Gemcitabine	Di Lorenzo et al <sup>4</sup>	RCT of intravesical gemcitabine vs. repeat BCG	- Patients failing BCG as per EAU 2008 guidelines (do not account for dose/duration of BCG or BCG refractory vs. relapsing disease)	- 19% of gemcitabine and 3% of repeat BCG patient free of disease at 2 years - ~35% progression for both groups

<sup>1</sup>Steinberg G, Bahnsen R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. *J Urol* 2000;163:761-7. <sup>2</sup>Adeo R, Caraglia M, Bellini S, et al. Randomized, phase 3 trial on gemcitabine vs. mitomycin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance. *J Clin Oncol* 2010;28:543-8. <sup>3</sup>Dalbagni G, Russo P, Ben-Porat L, et al. Phase 2 trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. *J Clin Oncol* 2006;24:2729-34. <sup>4</sup>Di Lorenzo G, Perdonà S, Damiano R, et al. Gemcitabine vs. bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: A multicenter, prospective, randomized trial. *Cancer* 2010;116:1893-900. BCG bacillus Calmette-Guérin; CIS: carcinoma in situ; EAU: European Association of Urology; LVI: lymphovascular invasion; MMC: mitomycin C; NMIBC: non-muscle-invasive bladder cancer; RCT: randomized control trial.

1. How do we define BCG failure when recruiting patients for clinical trials?
2. How do we appropriately combine patients who have CIS vs. high-grade papillary recurrence on BCG?
3. What is the most appropriate control group when comparing a novel therapy (e.g., cystectomy vs. repeat BCG vs. investigator's choice salvage therapy)?
4. Is it safe to delay cystectomy in operative candidates to evaluate a novel intravesical therapy?
5. What is the most clinically relevant outcome when weighing competing comorbidities in the NMIBC population (e.g., overall survival, disease-specific survival, response rates, recurrence)?

The FDA held a special meeting in 2013 in conjunction with representatives from the American Urological Association (AUA) to discuss these implications and to improve consensus on clinical trial design in BCG failure.<sup>36</sup> This collaboration triggered the subsequent evolution of the term "BCG-unresponsive"<sup>37,38</sup> and finally, a guidance document from the FDA for conducting clinical trials in this disease space.<sup>39</sup> A key objective of these initiatives was to define stringent inclusion criteria for clinical trials that would eliminate some of the patient heterogeneity encountered in prior studies.

Contributing to the heterogeneity of the NMIBC population are the differences in natural history and management of CIS compared to papillary tumors (Ta/T1). Patients with CIS are presumed to have residual disease at the time of starting intravesical therapy, while patients with papillary tumors have undergone complete resection of their disease. Disease eradication with novel therapies can, therefore, only be demonstrated in patients with CIS. As a result, the FDA typically requires that the primary endpoint of registration trials in the BCG-unresponsive disease state be the complete response (CR) rate in patients with CIS (with or with-

out concomitant papillary tumor). Patients with papillary tumors only are still included in the trials, and high-grade recurrence-free survival of these patients usually constitutes a co-primary or secondary endpoint of the trial. The FDA has suggested that an investigational agent should demonstrate a CR rate of 40–50% at six months for BCG-refractory CIS and a recurrence-free survival rate for Tis/Ta/T1 tumors of 30% at 18–24 months, with the lower limit of the 95% confidence interval excluding 20%. These numbers have been criticized for being unrealistic and some worry it will further deter drug development in an already challenging disease state.<sup>40</sup> It remains to be seen if the FDA will approve a novel therapy for both CIS and Ta/T1 patients based on this type of trial design, as the final approval decision will always be dependent on panel review of clinical trial results for the individual agent.

The FDA accepts single-arm, phase 2 trials for registration of novel therapies in patients with BCG-unresponsive NMIBC because there is consensus in the field that there is no appropriate control group to which to compare.<sup>39</sup> A placebo or further BCG would be considered unethical. One could consider randomization to radical cystectomy, but the feasibility of such a trial would be low. If a new agent is approved in the near future, standard clinical trial design could evolve to include randomization to the newly approved agent.

Another important question is whether cystectomy can be safely delayed to evaluate a novel therapy. Retrospective studies have shown that cystectomy can be delayed up to one year after initial TURBT in high-risk BCG-refractory urothelial carcinoma with no effect on disease-specific mortality.<sup>41</sup> Furthermore, prospective studies following the natural history of BCG treatment demonstrated that progression rarely occurs at six months and the median time to progression

of T1HG disease is approximately 24 months.<sup>42</sup> The recently presented preliminary data from the Keynote 057 trial also showed that none of 102 with BCG-unresponsive CIS progressed during a median of 15.8 months of followup.<sup>43</sup>

## Novel therapies

Therapies currently being investigated for BCG failure are summarized in Table 3, with certain examples highlighted in the text below.

### Enhanced intravesical chemotherapy

Device-assisted chemotherapy aims to improve the penetration of the drug through the urothelium using heat (chemohyperthermia; CHT) or electrical current (electromotive drug administration). Of the two, CHT has been studied more extensively in the setting of BCG failure.<sup>44-46</sup> The Synergo system (radiofrequency-induced thermochemotherapy [RITE]) uses a catheter microwave applicator to heat the bladder wall to 41–44°C, while concurrently running MMC through a parallel cooled circuit. Data on CHT are largely heterogeneous, with recurrence-free survival ranging from 25–50%.<sup>44</sup> Arends and colleagues<sup>47</sup> collected prospective data on high- and intermediate-risk NMIBC (81% had prior BCG) treated with MMC or epirubicin with CHT and report a two-year recurrence-free survival of approximately 50% for both agents. The recently reported HYMN trial randomized 104 intermediate- or high-risk patients after BCG failure to either RITE or “institutional standard second-line therapy” (i.e., electromotive mitomycin, repeat BCG, or conventional mitomycin).<sup>48</sup> There was no difference in disease-free survival or three-month CR rate in CIS patients. This trial, however, has been criticized for design concerns, particularly for the heterogeneity of the patient population, and the details of drug delivery, especially the dose of mitomycin delivered.<sup>49</sup> Van Valenberg and colleagues retrospectively examined the outcomes of patients with CIS ± papillary NMIBC receiving Synergo.<sup>50</sup> Among patients with a CR at six months, recurrence rates were 17.4% for BCG-unresponsive and 27.3% in other categories of BCG failure. However, only half of patients with BCG-unresponsive disease and 70% of other failures were able to achieve CR.

Another early concept is the use of standard intravesical chemotherapy agents incorporated into micelles. These nanoparticles are believed to act as mucoadhesives, improving the attachment of cytotoxic agents to the urothelium, increasing dwell time, and enhancing drug uptake.<sup>51</sup> A single-arm, phase 2 trial testing albumin-bound paclitaxel in 28 high-risk NMIBC patients with recurrence after BCG induction (i.e., not true BCG-unresponsive NMIBC) demonstrated recurrence-free survival of 18% and cancer-specific survival of 91% at a median followup of 41 months.<sup>52</sup> It is not clear

that these results are any better than would be anticipated with unencapsulated docetaxel. A clinical trial investigating intravesical hyperconjugated polyglycerol-encapsulated docetaxel is under way.<sup>53</sup>

### Photodynamic therapy

Photodynamic therapy uses light energy to eradicate malignant urothelial cells. Systems currently being investigated first require intravesical instillation of a photosensitizing agent followed by insertion of a urinary catheter capable of transmitting light from an external source. Bader et al<sup>54</sup> tested photodynamic therapy with hexaminolevulinatate in a small series of 17 patients with recurrent NMIBC. While the majority had high-grade disease, only 12 had prior BCG therapy, with no data on adequacy or nature of recurrence. Twelve percent of patients were tumor-free at 21 months. A phase 1 study investigating a different photosensitizer (TLD1433) has been completed<sup>55</sup> and a larger phase 2 trial in the BCG-unresponsive setting is planned.<sup>56</sup>

### Immunotherapy

Inhibitors of programmed cell death protein (PD1) and PD1 ligand (PDL1), (collectively termed immune checkpoint inhibitors) represent a major breakthrough in the treatment of patients with metastatic bladder cancer. These agents interrupt a negative regulatory signal that suppresses tumor cell killing by activated T-cells, thereby triggering an anti-tumor response.<sup>57,58</sup> Two registration trials are testing the efficacy of checkpoint inhibitors in BCG-unresponsive NMIBC.<sup>43,59</sup> Keynote 057 reported preliminary results at the annual meeting of the European Society of Medical Oncology in October 2018. The three-month CR rate in 102 patients with BCG-unresponsive CIS was 40.2%.<sup>43</sup> These therapies would represent a potential paradigm change for the management of patients with NMIBC since they are systemic therapies usually administered by medical oncologists in North America.

### Gene therapy

Gene therapy is one of the most active areas of translational research for bladder cancer, and three promising agents are in advanced stages of clinical development.

Adstiladrin<sup>®</sup> (rebranded from Instiladrin<sup>®</sup>; nadofaragene firadenovec) is a replication-deficient adenovirus programmed to express interferon-alpha that is administered together with an incipient Syn3 to promote uptake of the virus into tumor tissue. This agent has passed through phase 1 and 2 trials and is now being tested in a second large, single-arm trial (phase 3). Of 40 patients with BCG-unresponsive NMIBC in the phase 2 trial, 14 (35%) were

**Table 3. Ongoing clinical trials investigating novel agents in BCG failure**

Agent	Study	Study design	Inclusion criteria	Mechanism	Primary outcomes
<b>Enhanced intravesical chemotherapies</b>					
Synergo	NCT02471495	Phase 3, single-arm trial	Persistent CIS after induction plus maintenance BCG at 6 months, recurrent disease within 3 months of starting BCG, or disease progression	Microwave-emitting catheter to improve penetrance of MMC	Recurrence-free survival
Nanoxel	NCT02982395 <sup>47</sup>	Phase 3, double-arm, open-label study comparing nanoxel to mitomycin C	Any NMIBC “unresponsive” to BCG	Paclitaxel-containing micelles (nanoparticles)	Recurrence-free survival
Nab-Rapamycin (ABI-009)	NCT02009332	Combined phase 1 and 2, single-arm study	Phase 2: high-grade NMIBC BCG refractory <sup>1</sup> or relapsing <6 months despite adequate BCG	Rapamycin-containing micelles (nanoparticles)	Adverse events
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin	NCT02202772	Phase 1, single-arm	High-grade NMIBC with persistent or recurrent disease after BCG induction	Combination intravesical chemotherapy	Safety and tolerability
Photodynamic therapy	NCT03053635	Phase 1, single-arm	Any NMIBC with persistent tumor after adequate BCG or BCG intolerant	Instillation of photosensitizer (TLD1433) followed by transurethral irradiation	Safety and tolerability
<b>Immunotherapy</b>					
Durvalumab	NCT03317158	Multi-arm, phase 1/2 study comparing durvalumab ± BCG ± EBRT	Any-grade recurrent NMIBC despite adequate BCG	PD-1 inhibitor, enhancing T-cell mediated anti-tumor activity	Phase 1: Determine recommended combination doses Phase 2: 6-month relapse-free survival (RFS) CR rate
	NCT02901548	Phase 2, single-arm, open-label	BCG refractory or relapsing <9 months CIS only		
Pembrolizumab	NCT02808143	Phase 1, dose-escalation	High-grade NMIBC BCG refractory or relapsing <6 months despite adequate BCG.		Maximum tolerated dose of pembrolizumab CR rate Disease-free survival rate
	NCT02625961	Phase 2, single-arm, open-label	High-risk NMIBC unresponsive to adequate BCG (undefined)		
Atezolizumab	NCT02844816 <sup>50</sup>	Phase 2, single-arm, open-label	High-grade NMIBC BCG refractory or relapsing <6 months	PD-L1 inhibitor, enhancing T-cell mediated anti-tumour activity	CR rate Event-free survival
	NCT02792192	Phase 2, multi-arm trial comparing atezolizumab ± BCG stratified by BCG-unresponsive and relapsing disease	Any BCG-refractory or -relapsing NMIBC with CIS		Adverse events Maximum tolerated dose of BCG in combination with atezolizumab CR rate
ALT-801	NCT01625260	Phase 1b/2, single-arm trial of combination intravenous ALT-801 and intravesical gemcitabine	Any high-grade NMIBC, multifocal disease, or tumour >4 cm. BCG intolerant or recurrent disease after 1 course of BCG	Recombinant IL-2-T-cell receptor domain fusion protein. Potent IL-2 receptor agonist	Adverse events CR rate
PANVAC Vaccine	NCT02015104	Phase 2, RCT of BCG alone vs. BCG + PANVAC	Any high-grade NMIBC recurring after at least 1 induction course of BCG	Subcutaneous vaccine composed of viral vectors encoding common tumor antigens	Improved disease-free survival in PANVAC + BCG group

<sup>1</sup>The concepts BCG refractory, BCG relapsing, and adequate BCG are consistent with the definitions outlined in the text. BCG: bacillus Calmette Guerin; CIS: carcinoma in situ; CR: complete response; MMC: mitomycin C; NMIBC: non-muscle-invasive bladder cancer; RCT: randomized control trial.



<b>Table 3 (cont'd). Ongoing clinical trials investigating novel agents in BCG failure</b>					
<b>Agent</b>	<b>Study</b>	<b>Study design</b>	<b>Inclusion criteria</b>	<b>Mechanism</b>	<b>Primary outcomes</b>
<b>Recombinant intravesical therapies</b>					
rAd-IFN $\alpha$ /Syn3	NCT01687244	Phase 2, RCT comparing 2 doses	High-grade BCG relapsing or refractory NMIBC	Interferon- $\alpha$ expressing adenovirus	35% of patients free of high-grade disease at 12 months
	NCT02773849	Phase 3, single-arm, open-label	High-grade NMIBC BCG relapsing <12 months		CR rate in patients with CIS
Vicinium	Kowalski et al <sup>65</sup>	Phase 2, non-randomized, open-label trial comparing 6- vs. 12-week induction	High-grade NMIBC failing to respond to $\geq 1$ cycle of BCG or BCG-intolerant	Pseudomonas exotoxin-anti-EpCAM fusion protein	~ 40% CR in both groups at 3 months
	NCT02449239	Phase 3, single-arm	High-grade NMIBC with any recurrence/persistence despite adequate BCG		CR rate
CG0070 oncolytic virus	NCT02365818	Phase 2, single-arm trial	Any high-grade NMIBC that is BCG refractory or relapsing up to 24 months from last BCG exposure	GMCSF-expressing oncolytic virus	% with CR >12 months
<b>Other therapies</b>					
Sunitinib	NCT01118351	Phase 2, single-arm, open-label	Any recurrent NMIBC following BCG treatment	Tyrosine kinase inhibitor	CR rate
Vicinium + Durvalumab	NCT03258593	Phase 1, single-arm	High-grade NMIBC BCG refractory or relapsing	See above	Safety and tolerability

<sup>†</sup>The concepts BCG refractory, BCG relapsing, and adequate BCG are consistent with the definitions outlined in the text. BCG: bacillus Calmette Guerin; CIS: carcinoma in situ; CR: complete response; MMC: mitomycin C; NMIBC: non-muscle-invasive bladder cancer; RCT: randomized control trial.

free of high-grade recurrence at 12 months.<sup>60</sup> The phase 3 trial is an FDA registration trial.<sup>61</sup>

CG007 is a conditionally replicating oncolytic adenovirus that expresses granulocyte-monocyte colony-stimulating factor (GM-CSF). Viral replication and GM-CSF expression are directly and indirectly under the control of the E2F-1 promoter,<sup>62</sup> which is active only in cancer cells with loss of retinoblastoma (Rb). This provides tumor selectivity. After a successful phase 1 study that demonstrated safety and an early signal for efficacy,<sup>63</sup> CG0070 was tested in a single-arm, phase 2 trial in patients with BCG-unresponsive NMIBC.<sup>64</sup> The agent was administered weekly for a six-week induction course, followed by maintenance dosing at six, 12, and 18 months. Interim results from 45 patients revealed a 47% CR rate at six months. In a subsequent update<sup>65</sup> of these trial results in a meeting presentation, the CR rate at 12 months in 61 patients was 30% (27% in CIS and 38% in pure Ta/T1). Ten patients underwent cystectomy, of whom six had MIBC. Most of the adverse events were related to lower urinary tract symptoms, flu-like symptoms, and fatigue. Final results of this trial will determine if it can move towards FDA approval and clinical implementation.

BC-819 is a plasmid administered intravesically with polyethyleneimine, a cationic membrane permeabilizer.<sup>66</sup> The plasmid encodes the diphtheria toxin under the control of the H19 promoter sequence, an oncofetal transcription factor upregulated in urothelial carcinoma. Selective synthesis of diphtheria toxin in tumor cells causes arrest of protein

synthesis and subsequent cell death without compromising the benign urothelium. A phase 2 marker lesion trial was completed in 2013<sup>67</sup> for patients with intermediate-risk disease only (no high-grade or CIS) who had recurrent or persistent disease after at least one course of any intravesical therapy. The authors report that BC-819 eradicated one-third of all marker lesions and 40% of patients remained disease-free at two years. A trial testing BC-819 in BCG-unresponsive NMIBC has not yet launched.<sup>68</sup>

### Targeted therapy

Vicinium (oportuzumap monatox; VB4-845) is a recombinant protein comprised of a single chain variable fragment of a humanized anti-EpCAM antibody fused to Pseudomonas exotoxin A.<sup>69</sup> Its tumor specificity rests on increased plasma membrane expression of the EpCAM surface marker on urothelial carcinoma.<sup>70</sup> Binding of the anti-EpCAM component to EpCAM causes internalization of the Pseudomonas exotoxin by receptor-mediated endocytosis, and the toxin causes arrest of protein synthesis. Vicinium is, therefore, only efficacious against tumors expressing EpCAM, which has been a consistent inclusion criterion for enrolment in clinical trials.

In a phase 2 study with EpCAM-expressing CIS, most of which was BCG-refractory, 40% of patients obtained a CR and 16% remained disease-free at 18–25-month followup.<sup>71</sup> Results from a single-arm, phase 3 FDA registration trial in

patients with BCG-unresponsive NMIBC were reported in a company business report.<sup>72</sup> Vicinium was instilled into the bladder two times per week for six weeks followed by weekly for six weeks and every two weeks for up to two years. The CR rate in CIS patients was 39% at three months and 15% at 12 months.<sup>73</sup>

## Conclusions

The landscape of clinical trials in BCG failure has shifted dramatically from intravesical chemotherapy to novel gene, immune, and targeted therapies, with more consistent standards for patient selection and outcome reporting. Most studies remain single-arm trials due to the lack of a defined control to which to compare. Since the BCG-unresponsive patient population is still quite heterogeneous, it is impossible to compare drugs across trials. Encouraging early results have been reported for several agents, including Vicinium, Adstiladrin®, GC0070, and pembrolizumab, so that any one or more of these agents could obtain FDA approval in the U.S. in the near future. Once one or more agents are available in clinical practice, the clinical trial space will need to evolve to encompass comparison trials to the newly established effective agents. If multiple agents are approved, we will need to investigate whether there are markers to guide the use of one therapy over another, and to guide the best sequence of therapies. Combination therapies will be an important future area of clinical trial investigation. Furthermore, it remains to be seen how systemic delivery of a checkpoint inhibitor will be accepted in this patient population, especially if intravesical alternatives are available.

It is important to bear in mind that these therapies are being tested in patients who are ineligible for or decline cystectomy for BCG-unresponsive NMIBC. Many patients ultimately chose clinical trial participation over cystectomy, and some proceed to cystectomy if the trial agent does not work. With one or more effective, FDA-approved salvage therapy options for patients with BCG-unresponsive NMIBC, it will be even more important to identify in which patients it is safe to delay cystectomy.

**Competing interests:** Dr. Black has been an advisory board member or equivalent for Abbvie, Asieris, Astellas, AstraZeneca, Bayer, Biosyent, BMS, Janssen, Lilly, Merck, Roche, Sanofi, and Urogen; a speakers' bureau member for Abbvie, Biosyent, Ferring, Janssen, Pfizer, and TerSera; has received grants and/or honoraria from Bayer, GenomeDx Biosciences, iProgen, and Sanofi; has participated in clinical trials supported by Astellas, Ferring, Genentech, Janssen, MDx Health, and Sitka; and shares a patent with GenomeDx. Dr. Chehroudi reports no competing personal or financial interests related to this work.

This paper has been peer-reviewed.

## References

1. Kassouf W, Traboulsi SL, Kulkarni GS, et al. CUA guidelines on management of non-muscle-invasive bladder cancer. *Can Urol Assoc J* 2015;9:E690-704. <https://doi.org/10.5489/cuaj.3320>
2. Cancer.ca. Toronto: Canadian Cancer Society; c2019 [updated 2019]. Available at: <https://www.cancer.ca/en/cancer-information/cancer-type/bladder/statistics/?region=on>. Accessed July 20, 2019.
3. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. *CA Cancer J Clin* 2018;68:7-30. <https://doi.org/10.3322/caac.21442>
4. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. *Eur Urol* 2006;49:466-77. <https://doi.org/10.1016/j.eururo.2005.12.031>
5. Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle-invasive bladder cancer: AUA/SUO guideline. *J Urol* 2016;196:1021-9. <https://doi.org/10.1016/j.juro.2016.06.049>
6. Babjuk M, Böhle A, Burger M, et al. EAU guidelines of non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. *Eur Urol* 2017;71:447-61. <https://doi.org/10.1016/j.eururo.2016.05.041>
7. Kamat AM, Witjes JA, Brausi M, et al. Defining and treating the spectrum of intermediate risk non-muscle-invasive bladder cancer. *J Urol* 2014;192:305-15. <https://doi.org/10.1016/j.juro.2014.02.2573>
8. Matsumoto K, Kikuchi E, Yanai Y, et al. Characterizing intermediate-risk non-muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy. *Urol Oncol* 2017;35:208-14. <https://doi.org/10.1016/j.urolonc.2016.11.014>
9. Cookson MS, Herr HW, Zhang ZF, et al. The treated natural history of high-risk superficial bladder cancer: 15-year outcome. *J Urol* 1997;158:62-7. <https://doi.org/10.1097/00005392-199707000-00017>
10. Patard JJ, Chopin DK, Boccon-Gibod L. Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer. *World J Urol* 1993;11:165-8. <https://doi.org/10.1007/BF00211413>
11. Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs. transurethral resection alone in Ta and T1 bladder cancer. *BJU Int* 2001;88:209-16. <https://doi.org/10.1046/j.1464-410x.2001.02306.x>
12. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guérin vs. mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. *J Urol* 2003;169:90-5. [https://doi.org/10.1016/S0022-5347\(05\)64043-8](https://doi.org/10.1016/S0022-5347(05)64043-8)
13. Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C vs. bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. *Eur Urol* 2009;56:247-56. <https://doi.org/10.1016/j.eururo.2009.04.038>
14. Bohle A, Bock PR. Intravesical bacille Calmette-Guérin vs. mitomycin C in superficial bladder cancer: Formal meta-analysis of comparative studies on tumor progression. *Urology* 2004;63:682-6. <https://doi.org/10.1016/j.urology.2003.11.049>
15. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance BCG immunotherapy for recurrent Ta, T1, and CIS transitional cell carcinoma of the bladder: A randomized SWOG study. *J Urol* 2000;163:1124-9. [https://doi.org/10.1016/S0022-5347\(05\)67707-5](https://doi.org/10.1016/S0022-5347(05)67707-5)
16. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: One-third dose vs. full dose and 1 year vs. 3 years of maintenance. *Eur Urol* 2013;63:462-72. <https://doi.org/10.1016/j.eururo.2012.10.039>
17. Witjes JA. Management of BCG failures in superficial bladder cancer: A review. *Eur Urol* 2006;49:790-7. <https://doi.org/10.1016/j.eururo.2006.01.017>
18. Shirakawa H, Kikuchi E, Tanaka N, et al. Prognostic significance of bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer. *BJU Int* 2012;110:E216-21. <https://doi.org/10.1111/j.1464-410X.2011.10894.x>
19. Bretton PR, Herr HW, Kimmel M, et al. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guérin. *J Urol* 1990;143:710-2. [https://doi.org/10.1016/S0022-5347\(17\)40067-X](https://doi.org/10.1016/S0022-5347(17)40067-X)
20. Herr HW, Milan TN, Dalbagni G. BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: A prospective cohort outcomes study. *Urol Oncol* 2015;33:108.e1-4. <https://doi.org/10.1016/j.urolonc.2014.02.020>
21. Steinberg RL, Thomas LJ, Mott SL, et al. Bacillus Calmette-Guérin (BCG) treatment failures with non-muscle invasive bladder cancer: A data-driven definition for BCG-unresponsive disease. *Bladder Cancer* 2016;27:215-24. <https://doi.org/10.3233/BLC-150039>
22. Lerner SP, Tangen CM, Sucharew H, et al. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle-invasive bladder cancer. *Urol Oncol* 2009;2:155-9. <https://doi.org/10.1016/j.urolonc.2007.11.033>



23. Giannarini G, Birkhäuser FD, Recker F, et al. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra. *Eur Urol* 2014;65:825-31. <https://doi.org/10.1016/j.eururo.2013.09.049>
24. Catalona WJ, Hudson MA, Gillen DP, et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. *J Urol* 1987;137:220-4. [https://doi.org/10.1016/S0022-5347\(17\)43959-0](https://doi.org/10.1016/S0022-5347(17)43959-0)
25. O'Donnell MA, Boehle A. Treatment options for BCG failures. *World J Urol* 2006;24:481-7. <https://doi.org/10.1007/s00345-006-0112-0>
26. Coplen DE, Marcus MD, Myers JA, et al. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guérin: Analysis of possible predictors of response free of tumor. *J Urol* 1990;144:652-7. [https://doi.org/10.1016/S0022-5347\(17\)39546-0](https://doi.org/10.1016/S0022-5347(17)39546-0)
27. Haas CR, Barlow LJ, Badalato GM, et al. The timing of radical cystectomy for bacillus Calmette-Guérin failure: Comparison of outcomes and risk factors for prognosis. *J Urol* 2016;195:1704-9. <https://doi.org/10.1016/j.juro.2016.01.087>
28. Joudi FN, Smith BJ, O'Donnell MA, et al. Final results from a national, multicenter, phase 2 trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. *Urol Oncol* 2006;24:344-8. <https://doi.org/10.1016/j.urolonc.2005.11.026>
29. Gallagher BL, Joudi FN, Maymi JL, et al. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. *Urology* 2008;71:297-301. <https://doi.org/10.1016/j.urology.2007.09.050>
30. Steinberg G, Bahnsen R, Brosnan S, et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. *J Urol* 2000;163:761-7. [https://doi.org/10.1016/S0022-5347\(05\)67799-3](https://doi.org/10.1016/S0022-5347(05)67799-3)
31. Addeo R, Caraglia M, Bellini S et al. Randomized phase 3 trial on gemcitabine vs. mitomycin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance. *J Clin Oncol* 2010;28:543-8. <https://doi.org/10.1200/JCO.2008.20.8199>
32. Di Lorenzo G, Perdonò S, Damiano R, et al. Gemcitabine vs. bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: A multicenter, prospective, randomized trial. *Cancer* 2010;116:1893-900. <https://doi.org/10.1002/cncr.24914>
33. Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent non-muscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy. *J Urol* 2013;189:834-9. <https://doi.org/10.1016/j.juro.2012.10.068>
34. Steinberg RL, Thomas LJ, O'Donnell MA. Combination intravesical chemotherapy for non-muscle-invasive bladder cancer. *Eur Urol Focus* 2018;4:503-5. <https://doi.org/10.1016/j.euf.2018.07.005>
35. Babiuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. *Eur Urol* 2008;54:303-14. <https://doi.org/10.1016/j.eururo.2008.04.051>
36. Jarow JP, Lerner SP, Kluetz PG, et al. Clinical trial design for the development of new therapies for non-muscle-invasive bladder cancer: Report of a Food and Drug Administration and American Urological Association public workshop. *Urology* 2014;83:262-4. <https://doi.org/10.1016/j.urology.2013.10.030>
37. Jarow J, Mahler VE, Ibrahim A, et al. Development of systemic and topical drugs to treat non-muscle-invasive bladder cancer. *Bladder Cancer* 2015;1:133-6. <https://doi.org/10.3233/BLC-150016>
38. Lerner SP, Dinney C, Kamat A, et al. Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. *Bladder Cancer* 2015;1:29-30. <https://doi.org/10.3233/BLC-159002>
39. Food and Drug Administration. BCG-unresponsive non-muscle-invasive bladder cancer: Developing drugs and biologics for treatment guidance for industry. Feb 2018. Available at: <https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm529600.pdf>. Accessed Jan. 20, 2020.
40. Amrhein J, Kamat AM, Morales A. Re: Jarow JP et al. Clinical trial design for the development of new therapies for non-muscle-invasive bladder cancer: Report of a Food and Drug Administration and American Urological Association public workshop (*Urology* 2014;83:262-5). *Urology* 2014;84:494-5. <https://doi.org/10.1016/j.urology.2014.03.034>
41. Jäger W, Thomas C, Haag S, et al. Early vs. delayed radical cystectomy for 'high-risk' carcinoma not invading bladder muscle: Delay of cystectomy reduces cancer-specific survival. *BJU Int* 2011;108:E284-8. <https://doi.org/10.1111/j.1464-410X.2010.09980.x>
42. Millán-Rodríguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. *J Urol* 2000;164:680-4. [https://doi.org/10.1016/S0022-5347\(05\)67280-1](https://doi.org/10.1016/S0022-5347(05)67280-1)
43. Balar AV, Kulkarni GS, Uchio E, et al. Keynote 057: Phase 2 trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG). *J Clin Oncol* 2019; 37(suppl7):350. [https://doi.org/10.1200/JCO.2019.37.7\\_suppl.350](https://doi.org/10.1200/JCO.2019.37.7_suppl.350)
44. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: A systematic review. *Eur Urol* 2011;60:81-93. <https://doi.org/10.1016/j.eururo.2011.04.023>
45. Di Stasi SM, Giannantoni A, Giurliani A, et al. Sequential BCG and electromotive mitomycin vs. BCG alone for high-risk superficial bladder cancer: A randomized controlled trial. *Lancet Oncol* 2006;7:43-51. [https://doi.org/10.1016/S1470-2045\(05\)70472-1](https://doi.org/10.1016/S1470-2045(05)70472-1)
46. Racioppi M, Di Gianfrancesco L, Ragonese M, et al. ElectroMotive drug administration (EMDA) of mitomycin C as first-line salvage therapy in high risk "BCG failure" non-muscle-invasive bladder cancer: 3 years' followup outcomes. *BMC Cancer* 2018;18:1224. <https://doi.org/10.1186/s12885-018-5134-7>
47. Arends TJ, van der Heijden AG, Witjes JA, et al. Combined chemohyperthermia: 10-year, single-center experience in 160 patients with non-muscle-invasive bladder cancer. *J Urol* 2014;192:708-13. <https://doi.org/10.1016/j.juro.2014.03.101>
48. Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced thermo-chemotherapy effect vs. a second course of bacillus Calmette-Guérin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance bacillus-Calmette Guérin therapy (HYMN): A phase 3, open-label, randomized, controlled trial. *Eur Urol* 2019;75:63-71. <https://doi.org/10.1016/j.eururo.2018.09.005>
49. Witjes JA. Radiofrequency-induced thermochemotherapy for recurrent non-muscle-invasive bladder cancer: A new treatment for an unmet need? *Eur Urol* 2019;75:72-3. <https://doi.org/10.1016/j.eururo.2018.09.039>
50. Van Valenberg FJP, Kajtazovic A, Canepa G, et al. Intravesical radiofrequency-induced chemohyperthermia for carcinoma in situ of the urinary bladder: A retrospective, multicenter study. *Bladder Cancer* 2018;4:365-76. <https://doi.org/10.3233/BLC-180187>
51. Mugabe C, Hadaschik BA, Kainthan RK, et al. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. *BJU Int* 2009;103:978-86. <https://doi.org/10.1111/j.1464-410X.2008.08132.x>
52. Robins DJ, Sui W, Matulay JT, et al. Long-term survival outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder cancer after previous bacillus Calmette-Guérin therapy. *Urology* 2017;103:149-53. <https://doi.org/10.1016/j.urology.2017.01.018>
53. Clinicaltrials.gov. Bethesda: US National Library of Medicine; c2016 [updated April 18, 2018]. Available at: <https://clinicaltrials.gov/ct2/show/NCT02982395?term=docetaxel&recrs=a&cond=bladder+cancer&rank=1>. Accessed April 15, 2019.
54. Bader MJ, Stepp H, Beyer W, et al. Photodynamic therapy of bladder cancer — a phase 1 study using hexaminolevulinate (HAL). *Urol Oncol* 2013;31:1178-83. <https://doi.org/10.1016/j.urolonc.2012.02.007>
55. Clinicaltrials.gov. Bethesda: US National Library of Medicine; c2017 [updated August 20, 2018]. Available at: <https://clinicaltrials.gov/ct2/show/NCT03053635>. Accessed April 15, 2019.
56. Clinicaltrials.gov. Bethesda: US National Library of Medicine; c2019 [updated May 10, 2019]. Available at: <https://clinicaltrials.gov/ct2/show/NCT03945162>. Accessed July 20, 2019.
57. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. *N Engl J Med* 2017;376:1015-26. <https://doi.org/10.1056/NEJMoa1613683>
58. Balar AV, Castellano D, O'Donnell PH, et al. Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population. Presented at ASCO-GU 2017; abstract #284. Available at: [https://doi.org/10.1200/JCO.2017.35.6\\_suppl.284](https://doi.org/10.1200/JCO.2017.35.6_suppl.284). Accessed Jan. 20, 2020.
59. Clinicaltrials.gov. Bethesda: US National Library of Medicine; c2016 [updated May 27, 2019]. Available at: [https://clinicaltrials.gov/ct2/show/study/NCT02844816?show\\_locs=Y#locn](https://clinicaltrials.gov/ct2/show/study/NCT02844816?show_locs=Y#locn). Accessed May 28, 2019.
60. Shore ND, Boorjian SA, Canter DJ, et al. Intravesical rAd-IFN $\gamma$ /Syn3 for patients with high-grade, bacillus Calmette-Guérin-refractory or relapsed non-muscle-invasive bladder cancer: A phase 2 randomized study. *J Clin Oncol* 2017;35:3410-6. <https://doi.org/10.1200/JCO.2017.72.3064>
61. Clinicaltrials.gov. Bethesda: US National Library of Medicine; c2016 [updated May 24, 2018]. Available at: <https://clinicaltrials.gov/ct2/show/NCT02773849>. Accessed May 15, 2019.
62. Ramesh N, Ge Y, Ennist DL, et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor — armed oncolytic adenovirus for the treatment of bladder cancer. *Clin Cancer Res* 2006;12:305-13. <https://doi.org/10.1158/1078-0432.CCR-05-1059>
63. Burke JM, Lamm DL, Meng MV, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of non-muscle-invasive bladder cancer. *J Urol* 2012;188:2391-7. <https://doi.org/10.1016/j.juro.2012.07.097>
64. Packiam VT, Lamm DL, Barocas DA, et al. An open label, single-arm, phase 2, multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. *Urol Oncol* 2018;36:440-7. <https://doi.org/10.1016/j.urolonc.2017.07.005>

65. Packiam VT, Barocas DA, Chamie K, et al. LBA24 C60070, an oncolytic adenovirus, for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC): 12-month interim results from a multicenter, phase 2 trial. *J Urol* 2018;199:e1166. <https://doi.org/10.1016/j.juro.2018.03.096>

66. Amit D, Hochberg A. Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. *J Transl Med* 2010;8:134. <https://doi.org/10.1186/1479-5876-8-134>

67. Gofrit ON, Benjamin S, Halachmi S, et al. DNA based therapy with diphtheria toxin-A BC-819: A phase 2b marker lesion trial in patients with intermediate risk non-muscle-invasive bladder cancer. *J Urol* 2014;191:1697-702. <https://doi.org/10.1016/j.juro.2013.12.011>

68. Clinicaltrials.gov. Bethesda: US National Library of Medicine; c2018 [updated May 3, 2019]. Available at: <https://clinicaltrials.gov/ct2/show/NCT03719300>. Accessed May 15, 2019.

69. Biggers K, Scheinfeld N. VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer. *Curr Opin Mol Ther* 2008;10:176-86.

70. Brunner A, Prelog M, Verdorfer J, et al. EpCAM is predominantly expressed in high-grade and advanced stage urothelial carcinoma of the bladder. *J Clin Pathol* 2008;61:307-10. <https://doi.org/10.1136/jcp.2007.049460>

71. Kowalski M, Guindon J, Brazas L, et al. A phase 2 study of oportuzumab monatox: An immunotoxin therapy for patients with non-invasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin. *J Urol* 2012;188:1712-8. <https://doi.org/10.1016/j.juro.2012.07.020>

72. Sesebio.com. Massachusetts: Sese Bio Financial Report, c2019 [updated May 13, 2019]. Available at: <https://ir.sesebio.com/news-releases/news-release-details/sesebio-reports-first-quarter-2019-financial-results-and>. Accessed May 9, 2020.

73. Clinicaltrials.gov. Bethesda: US National Library of Medicine; c2017 [updated May 9, 2019]. Available at: <https://clinicaltrials.gov/ct2/show/NCT03258593>. Accessed May 15, 2019.

**Correspondence:** Dr. Peter Black, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; [pblack@mail.ubc.ca](mailto:pblack@mail.ubc.ca)

To answer the multiple-choice questions associated with this article, go to: [www.cuasection3credits.org/cuajjune2020](http://www.cuasection3credits.org/cuajjune2020). This program is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians & Surgeons of Canada, and approved by the Canadian Urological Association. Remember to visit MAINPORT ([www.mainport.org/mainport/](http://www.mainport.org/mainport/)) to record your learning and outcomes. You may claim a maximum of 1 hour of credit.

**CUAJ is now offering its readers the opportunity to claim Section 3 Self-Assessment credits of the Maintenance of Certification (MOC) Program!**

Every second issue (February, April, June, August, October, and December), a specific paper will be accredited by the Canadian Urological Association (CUA).

**CLAIM YOUR CREDITS IN 3 EASY STEPS:**

- 1** Go to [www.cuaj.ca](http://www.cuaj.ca), read the accredited paper, and answer the three multiple choice questions associated with it.
- 2** Enter your name and email to receive a certificate of participation from CUA.
- 3** Log the self-learning activity and record learning/outcomes in your Royal College MAINPORT account.



[cuaj.ca](http://cuaj.ca)

